SCHEMBL163995

SCHEMBL163995

CC(C)(C)OC(=O)c1cc([O])c2cc3ccccc3cc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.38
GABRA1 P14867 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRA2 P47869 2/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GABRB1 P18505 2/20 0.37
GABRB2 P47870 2/20 0.37
SLC7A5 Q01650 1/20 0.36
ABCB1 P08183 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36
GABRG1 Q8N1C3 1/20 0.36
GABRG3 Q99928 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162581 0.88 ABCG2 (0.42) ABCG2GABRA1GABRG2GABRB3GABRA3
SCHEMBL162792 0.83 TSHR (0.47) MEN1KMT2ACA12CA1CA2
SCHEMBL163117 0.80 ALDH1A1 (0.44) ABCG2GABRA1GABRG2GABRB3GABRA3
SCHEMBL539749 0.80 CES2 (0.48) ABCG2GABRA1GABRG2GABRB3GABRA3
SCHEMBL163819 0.79 CA12 (0.50) MEN1KMT2ACA12CA1CA2
SCHEMBL160305 0.79 CA12 (0.50) MEN1KMT2ACA12CA1CA2
SCHEMBL1415273 0.78 CES2 (0.55) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL161660 0.77 LMNA (0.54) MEN1KMT2ACA12CA1CA2
SCHEMBL162474 0.77 MEN1 (0.46) MEN1KMT2AHPGDS
SCHEMBL163231 0.76 ALDH1A1 (0.49) MEN1KMT2AATMALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 ABCG2 1663/4885GABRA1 3545/4885GABRG2 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.